Physician profile
Marcie E Kable
NPI 1750645644
$1,725.83
in general payments reported to CMS, 2019-2025
25 companies · $676 in 2025
The $676 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $150 · 2023: $380 · 2024: $285 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,240.68 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $277.55 | 2021-2024 | Brilinta, Farxiga |
| Kestra Medical Technology Services, INC. | $156.88 | 2023-2025 | Assure Wcd |
| Abbott Laboratories | $135.17 | 2022-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $120.38 | 2021-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $118.32 | 2021-2025 | |
| Recor Medical INC | $114.55 | 2025 | Paradise Ultrasound Renal Denervation System |
| Novo Nordisk INC | $103.47 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $81.04 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.29 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $70.11 | 2023-2025 | Camzyos, Eliquis |
| Atricure, INC. | $61.95 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $50.93 | 2021-2025 | |
| Boston Scientific Corporation | $45.93 | 2022 | |
| Pfizer INC. | $39.53 | 2024-2025 | |
| Abiomed | $38.60 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $34.89 | 2025 | |
| Medtronic, INC. | $33.29 | 2024 | Symplicity G3 |
| Amgen INC. | $29.76 | 2023-2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $26.58 | 2023 | Opsumit, Uptravi |
| Bridgebio Pharma, INC. | $20.86 | 2025 | Attruby |
| Cordis US Corp. | $20.68 | 2025 | Mynx Control Venous |
| Cmp Pharma, INC. | $17.53 | 2022 | |
| Daiichi Sankyo INC. | $17.08 | 2024 | Injectafer |
| United Therapeutics Corporation | $16.39 | 2025 | Tyvaso |
| Sanofi-Aventis U.S. LLC | $14.07 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcie Kable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.